Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rufinamide in Generalized Anxiety Disorder
NCT00595231Phase 2Completed
- Sponsor
- Biotie Therapies
- Start
- Mar 2008
- Primary completion
- Oct 2008
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rufinamide in generalized anxiety disorder (GAD), sponsored by Biotie Therapies. Started Mar 2008; status: completed.
02
Drugs
rufinamide
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00595231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00595231.